A doença de Chagas, uma infecção parasitária amplamente distribuída na América Latina, é um problema grave de saúde pública com conseqüências devastadoras em termos de morbidade e mortalidade humana. A enzima cruzaína é a principal cisteíno protease do Trypanosoma cruzi, agente etiológico da tripanossomíase Americana ou doença de Chagas, e foi selecionada como alvo atrativo para o desenvolvimento de novos fármacos tripanocidas. No presente trabalho, a síntese e os efeitos inibitórios de uma série de trinta e três chalconas e sete hidrazidas são descritos contra a enzima cruzaína de T.cruzi. A maioria dos compostos mostraram inibição promissora in vitro (valores de IC 50 na faixa de 20-60 μM), o que sugere o potencial desses compostos como candidatos a líderes para contínuo desenvolvimento. Doze compostos são inéditos, sendo que quatro destes (7, 13, 16 e 18) estão entre os inibidores mais potentes da série.
Introduction
Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is a major cause of illness, morbidity, long-term disability, and death in Latin America. It is estimated that about 16-18 million people are infected and other 100 million are at risk of infection, with more than 50,000 deaths each year. In spite of the alarming health, economic, and social consequences of this parasitic infection, the limited existing drug therapy (nifurtimox and benznidazole) suffers from a combination of drawbacks including poor efficacy, and serious side effects. Therefore, there is an urgent need for new chemotherapeutic agents with novel mechanisms of action. [1] [2] [3] Enzymes are extremely attractive targets for small molecule drug intervention in human diseases. 1, 2 One important drug target is the major cysteine protease from T. cruzi, cruzain (EC 3. 4.22.51 ). This enzyme is implicated in several vital processes of the parasite, playing a pivotal role during the infection of host cells, replication, and metabolism. The identification and design of potent and selective cruzain inhibitors is, therefore, of great importance. About one decade ago, in a review of inhibitors of cysteine proteases, Otto and Schirmeister 4 cited a series of chalcone derivatives as inhibitors of malarial cysteine proteases. However, the potential of this class of inhibitors has not been fully explored, in spite of its synthetic versatility and potential low toxicity. 5 To the best of our knowledge, only two chalcones were reported as inhibitors of T. cruzi cruzain. 6 In that respect, there is a justifiable interest in developing structure-activity relationships (SAR) for this class of compounds. On the other hand, acylhydrazides (a class of compounds structurally related to chalcones) have been successfully investigated against T. cruzi cruzain. 7 In addition, both chalcone and acylhydrazide derivatives were active in vitro against T. brucei and T. cruzi. 8, 9 As part of our research program aimed at discovering novel T. cruzi cruzain inhibitors, we have synthesized and evaluated a series of chalcones and hydrazides. [10] [11] [12] 
Results and Discussion

Synthesis
The chalcone derivatives (Table 1) were prepared by aldolic condensation of aromatic aldehydes and corresponding acetophenone (Scheme 1), with yields ranging from 18 to 92%. 12 Chalcones 1 and 2 are derived from 3,4-methylenedioxybenzaldehyde; chalcones 3-6 are derived from 2-hydroxy-3-bromo-4,6-dimethoxyacetophenone (prepared as previously described, with yield of 95%); 13 chalcones 7-20 are derived from 3,4-methylenedioxyacetophenone; chalcones 21-27 are derived from 2-naphthylacetophenone; chalcones 28-31 are derived from 2,4,5-trimethoxyacetophenone (prepared as previously described, with yield of 81%); 14 and chalcones 32 and 33 are derived from 2,4-dimethoxyacetophenone. The benzylated vanillin (3-methoxy-4-(phenylmethoxy)-benzaldehyde) used to prepare chalcone 33 was obtained according to the procedure of Tsai and Klinman, 15 with yield of 88%.
The hydrazides (34-40) were prepared by condensation of the obtained 3,4,5-trimethoxybenzohydrazide (41) (previously prepared as described, with yield of 80%) 16 and corresponding aromatic aldehydes, with yields ranging from 61 to 72% (Scheme 2). 17 All synthesized compounds, including those that had been previously reported (chalcones 1, 2 
Biochemical evaluation of the synthetic compounds
As can be seen (Table 1) The IC 50 values of compounds 15, 22, 26, 27 (IC 50s > 25 μM), 11, 17, 19, 23, 24, and 37 (IC 50s > 50 μM), as well as of compounds 2, 31 and 32 (the weakest inhibitors of the series with IC 50s > 100 μM), could not be determined accurately due to solubility limitations that appeared to decrease the sensitivity of the assay. The most potent inhibitors of the series, 1, 5, 7, 10, 13, 16, and 18 (IC 50 values between 20 and 25 μM) represent a new class of lead candidates for further development. Furthermore, with a single exception of compound 5, all chalcone derivatives possess the methylenedioxyphenyl (1,3-benzodioxole) moiety, which suggests a significant contribution of this group to the observed activity. In addition, it is worth noting that chalcones 7, 13, 16 and 18 are newly synthesized compounds and are among the most promising compounds for further SAR studies. On the other hand, the hydrazide derivatives (34-40) investigated in this work showed only moderate inhibitory potency, with IC 50 values in the range of 40-60 μM.
Conclusions
A series of chalcones and hydrazides have been prepared and evaluated in vitro against cruzain from T. cruzi. Most compounds showed promising inhibitory activity against the parasite enzyme, with IC 50 values in the low micromolar range. Our results demonstrate the potential of these compounds as a new class of small molecule inhibitors of T. cruzi cruzain. Future efforts to optimize these compounds will involve the design, synthesis and SAR studies of a variety of more watersoluble derivatives, as well as investigation about the importance of methylenedioxyphenyl moiety side in the structure of chalcones through the determination of the possible mechanism of enzyme inhibition and inhibitor binding mode. Efforts in this direction are in progress, and will be reported in due course.
Experimental
Physicochemical data of the synthesized compounds
The purified compounds were obtained in yields ranging from 18 to 92%. Melting points were determined with a Microquímica MGAPF-301 apparatus and are uncorrected. IR spectra were recorded with an Abb Bomen FTLA 2000 spectrometer on KBr disks. NMR ( 1 H and 13 C NMR) were recorded on a Varian Oxford AS-400 (400 MHz) spectrometer, using tetramethylsilane as an internal standard. Elemental analysis was carried out with a CHNS EA 1110. Percentages of C and H were in agreement with the product formula (within + 0.4% of theoretical values of C).
General procedure for the synthesis and purification of chalcones The chalcones were synthesized as shown in Scheme 1. All reagents used in this work were analytical grade and were purchased from Merck and Sigma-Aldrich. Exceptions are 2-hydroxy-3-bromo-4,6-dimethoxyacetophenone, 2,4,5-trimethoxyacetophenone and 3-methoxy-4-(phenylmethoxy)-benzaldehyde, which were prepared as previously described. [13] [14] [15] The chalcones (1-33) were prepared by magnetic stirrer of the acetophenone derivative (1.2 mmol), methanol (20 mL), KOH 50% m/v (5 mL), and the corresponding aldehyde (1.2 mmol), at room temperature for 24 h. Distilled water and hydrochloric acid (10%) were added to the reaction for total precipitation of the products. The compounds were then obtained by vacuum filtration and later recrystallized from dichloromethane and hexane. Chalcones 1, 2, 4, 5, 8-12, 14, 17, 19, 21, 23-26, 28 , 31-33 were previously described in the literature, 18 while compounds 3, 6, 7, 13, 15, 16, 18, 20, 22 , 27, 29 and 30 are novel compounds which have not been reported. The chalcones (3) (4) (5) (6) showed yields in the range of 40-50% due the presence of the bromine atom in the starting material acetophenone, which stabilizes the enolate intermediate of the reaction making it less reactive. This effect was not observed for the chalcones (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , which showed yields in the range of 70-98%.
(2E)-1-(2'-Hydroxy,3'-bromo,4',6'-dimethoxyphenyl)-3-(1-naphthyl)-2-propen-1-one (3)
Yellow solid; mp 218-219ºC; yield: 42%; 1 
(2E)-1-(2'-Hydroxy-3'-bromo-4',6'-dimethoxyphenyl)-3-(4-buthoxyphenyl)-2-propen-1-one (6)
Yellow (2E)-1-(1,3-Benzodioxol-5-yl)-3-(2,6-dichlorophenyl) 
(2E)-1-(1,3-Benzodioxol-5-yl)-3-(1-naphthyl)-2-propen-1-one (13)
Yellow solid; mp 137-139 ºC; yield: 91%; 
